Considering neuroprotective and antioxidant effects of trigonelline, our study was undertaken to evaluate its protective effect in a 6-hydroxydopamine-induced model of Parkinson’s disease (PD) in rats. Unilateral intrastriatal 6-OHDA-lesioned rats were pretreated with trigonelline at doses of 50 and 100 mg/kg. Significant rotational behavior, a significant reduction in the number of Nissl-stained neurons on the left side of the substantia nigra pars compacta (SNC), increased apoptosis, enhanced levels of malondialdehyde (MDA) and nitrite, and a lower level of glutathione (GSH) were observed in 6-OHDA-lesioned rats. Trigonelline at a dose of 100 mg/kg significantly reduced rotations, prevented reduction of SNC neurons, prevented apoptosis, and restored the MDA level. These results suggest that pre-lesion trigonelline treatment exerts dose-dependent neuroprotective and antiapoptotic effects under conditions of 6-OHDA toxicity and may be, henceforth, advantageous for the management of early PD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
J. Massano and K. P. Bhatia, “Clinical approach to Parkinson’s disease: features, diagnosis, and principles of management,” Cold Spring Harb. Perspect. Med., 2, No. 6, a008870 (2012).
K. Wirdefeldt, H. O. Adami, P. Coleand, et al., “Epidemiology and etiology of Parkinson’s disease: a review of the evidence,” Eur. J. Epidemiol., 26 Suppl 1, S 1-58 (2011).
H. S. Lindgren and S. B. Dunnett, “Cognitive dysfunction and depression in Parkinson’s disease: what can be learned from rodent models?,” Eur. J. Neurosci., 35, No. 12, 1894-1907 (2012).
A. Reeve, E. Simcox, and D. Turnbull, “Ageing and Parkinson’s disease: Why is advancing age the biggest risk factor?,” Ageing Res. Rev., 14C, 19-30 (2014).
T. Foltynie and J. Kahan, “Parkinson’s disease: an update on pathogenesis and treatment,” J. Neurol., 260, No. 5, 1433-1440 (2013).
C. Ossig and H. Reichmann, “Treatment of Parkinson’s disease in the advanced stage,” J. Neural Transm., 120, No. 4, 523-529 (2013).
T. Baluchnejadmojarad, M. Roghani, and M. Mafakheri, “Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress,” Neurosci. Lett., 480, No. 3, 206-210 (2010).
M. Roghani, A. Niknam, M. R. Jalali-Nadoushanand, et al., “Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism,” Brain Res. Bull., 82, Nos. 5-6, 279-283 (2010).
S. E. Seidl, J. A. Santiago, H. Bilykand, et al., “The emerging role of nutrition in Parkinson’s disease,” Front. Aging Neurosci., 6, 36 (2014).
S. V. More, H. Kumar, S. M. Kangand, et al., “Advances in neuroprotective ingredients of medicinal herbs by using cellular and animal models of Parkinson’s disease,” Evid. Based Complement. Alternat. Med., 2013, 957875 (2013).
O. Yoshinari, A. Takenake, and K. Igarashi, “Trigonelline ameliorates oxidative stress in type 2 diabetic Goto-Kakizaki rats,”ʼ J. Med. Food, 16, No. 1, 34-41 (2013).
W. J. Yen, B. S. Wang, L. W. Changand, et al., “Antioxidant properties of roasted coffee residues,” J. Agric. Food Chem., 53, No. 7, 2658-2663 (2005).
B. N. Hong, T. H. Yi, S. Y. Kimand, et al., “High-dosage pyridoxine-induced auditory neuropathy and protection with coffee in mice,” Biol. Pharm. Bull., 32, No. 4, 597-603 (2009).
C. Tohda, T. Kuboyama, and K. Komatsu, “Search for natural products related to regeneration of the neuronal network,” Neurosignals, 14, Nos. 1-2, 34-45 (2005).
V. Gaur, S. L. Bodhankar, V. Mohanand, et al., “Neurobehavioral assessment of hydroalcoholic extract of Trigonella foenum-graecum seeds in rodent models of Parkinson’s disease,” Pharm. Biol., 51, No. 5, 550-557 (2013).
G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd ed, Academic Press, San Diego (1986).
T. Baluchnejadmojarad and M. Roghani, “Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress,” Behav. Brain Res., 224, No. 2, 305-310 (2011).
A. Claiborne, “Catalase activity,” in: CRC Handbook of Methods for Oxygen Radical Research, R. A. Greenwald, ed., Boca Raton, pp. 283–284 (1985).
J. Sedlak and R. H. Lindsay, “Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent,” Anal. Biochem., 25, No. 1, 192-205 (1968).
G. L. Ellman, “Tissue sulfhydryl groups,” Arch. Biochem. Biophys., 82, No. 1, 70-77 (1959).
M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” Anal. Biochem., 72, 248-254 (1976).
S. Afshin-Majd, M. Khalili, M. Roghaniand, et al., “Carnosine exerts neuroprotective effect against 6-hydroxydopamine toxicity in hemiparkinsonian rat,” Mol. Neurobiol. 51, No. 3, 1064-1070 (2014).
V. P. Chou, N. Ko, T. R. Holmanand, et al., “Geneenvironment interaction models to unmask susceptibility mechanisms in Parkinson’s disease,” J. Vis. Exp., 83, e50960. doi: 10.3791/50960. (2014).
A. Schober, “Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP,” Cell Tissue Res., 318, No. 1, 215-224 (2004).
R. K. Schwarting and J. P. Huston, “Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions,” Neurotoxicology, 18, No. 3, 689-708 (1997).
M. Jalali-Nadoushan and M. Roghani, “Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism,” Brain Res., 1505, 68-74 (2013).
P. Foley and P. Riederer, “Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease,” J. Neurol., 247, Suppl 2, 1182-1194 (2000).
J. Lotharius and P. Brundin, “Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein,” Nat. Rev. Neurosci., 3, No. 12, 932-942 (2002).
O. von Bohlen und Halbach, A. Schober, and K. Krieglstein, “Genes, proteins, and neurotoxins involved in Parkinson’s disease,” Prog. Neurobiol., 73, No. 3, 151-177 (2004).
S. Chen and W. Le, “Neuroprotective therapy in Parkinson disease,” Am. J. Ther., 13, No. 5, 445-457 (2006).
F. Zhou, J. Y. Wu, X. L. Sunand, et al., “Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation,” Neuropsychopharmacology, 32, No. 12, 2570-2580 (2007).
J. Miklossy, D. D. Doudet, C. Schwaband, et al., “Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys,” Exp. Neurol., 197, No. 2, 275-283 (2006).
K. Sriram and J. P. O’Callaghan, “Divergent roles for tumor necrosis factor-alpha in the brain,” J. Neuroimmune Pharmacol., 2, No. 2, 140-153 (2007).
C. K. Hwang and H. S. Chun, ʻʻIsoliquiritigenin isolated from licorice Glycyrrhiza uralensis prevents 6-hydroxydopamine-induced apoptosis in dopaminergic neurons,ʼʼ Biosci. Biotechnol. Biochem., 76, No. 3, 536-543 (2012).
A. E. Ghule, S. S. Jadhav, and S. L. Bodhankar, “Trigonelline ameliorates diabetic hypertensive nephropathy by suppression of oxidative stress in kidney and reduction in renal cell apoptosis and fibrosis in streptozotocin induced neonatal diabetic (nSTZ) rats,” Int. Immunopharmacol., 14, No. 4, 740-748 (2012).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mirzaie, M., Khalili, M., Kiasalari, Z. et al. Neuroprotective and Antiapoptotic Potential of Trigonelline in a Striatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease. Neurophysiology 48, 176–183 (2016). https://doi.org/10.1007/s11062-016-9586-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11062-016-9586-6